
**Ireland-Dublin: Medicinal products for the blood, blood-forming organs and the cardiovascular system
2023/S 115-355453**

Contract notice

Supplies

Legal Basis:

Directive 2014/24/EU

Section I: Contracting authority

I.1) Name and addresses

Official name: Irish Blood Transfusion Service
Postal address: National Blood Centre , James's Street
Town: Dublin
NUTS code: IE Éire / Ireland
Postal code: D08 NH5R
Country: Ireland
Contact person: Brian Boland
E-mail:

Internet address(es):

Main address:
Address of the buyer profile:

I.2) Information about joint procurement

The contract is awarded by a central purchasing body

I.3) Communication

Access to the procurement documents is restricted. Further information can be obtained at:
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be submitted electronically

I.4) Type of the contracting authority

Body governed by public law

I.5) Main activity

Health

Section II: Object

II.1) Scope of the procurement

II.1.1) Title:

Fibrinogen concentrate used for congenital afibrinogenaemia and dysfibrinogenaemia

II.1.2) Main CPV code

33620000 Medicinal products for the blood, blood-forming organs and the cardiovascular system

II.1.3) Type of contract

Supplies

II.1.4) Short description:

Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.

II.1.5) **Estimated total value**

II.1.6) **Information about lots**

This contract is divided into lots: no

II.2) **Description**

II.2.2) **Additional CPV code(s)**

33621000 Medicinal products for the blood and blood-forming organs

33622000 Medicinal products for the cardiovascular system

II.2.3) **Place of performance**

NUTS code: IE Éire / Ireland

II.2.4) **Description of the procurement:**

Human fibrinogen concentrate is used for congenital afibrinogenaemia and dysfibrinogenaemia states for treatment of bleeding complications. It is also used in acquired hypofibrinogenemia conditions such as massive haemorrhage, acquired coagulopathy, liver disease with bleeding and in obstetric haemorrhage. The product should be licensed for these clinical indications and approved by the HPRA. Fibrinogen, in presence of thrombin, activates FVIII and calcium, which is necessary to convert fibrinogen into stable three-dimensional fibrin coagula. The IBTS is responsible for the distribution of fibrinogen to users nationwide. IBTS must therefore have a sufficient stock and a stable supply of fibrinogen concentrates to meet patient needs.

II.2.5) **Award criteria**

Price is not the only award criterion and all criteria are stated only in the procurement documents

II.2.6) **Estimated value**

II.2.7) **Duration of the contract, framework agreement or dynamic purchasing system**

Duration in months: 36

This contract is subject to renewal: yes

Description of renewals:

As per RFT

II.2.10) **Information about variants**

Variants will be accepted: no

II.2.11) **Information about options**

Options: no

II.2.13) **Information about European Union funds**

The procurement is related to a project and/or programme financed by European Union funds: no

II.2.14) **Additional information**

Section III: Legal, economic, financial and technical information

III.1) **Conditions for participation**

III.1.2) **Economic and financial standing**

Selection criteria as stated in the procurement documents

-
- III.1.3) **Technical and professional ability**
Selection criteria as stated in the procurement documents

Section IV: Procedure

- IV.1) **Description**
- IV.1.1) **Type of procedure**
Open procedure
- IV.1.3) **Information about a framework agreement or a dynamic purchasing system**
- IV.1.8) **Information about the Government Procurement Agreement (GPA)**
The procurement is covered by the Government Procurement Agreement: no
- IV.2) **Administrative information**
- IV.2.2) **Time limit for receipt of tenders or requests to participate**
Date: 28/07/2023
Local time: 12:00
- IV.2.3) **Estimated date of dispatch of invitations to tender or to participate to selected candidates**
- IV.2.4) **Languages in which tenders or requests to participate may be submitted:**
English
- IV.2.6) **Minimum time frame during which the tenderer must maintain the tender**
Duration in months: 3 (from the date stated for receipt of tender)
- IV.2.7) **Conditions for opening of tenders**
Date: 28/07/2023
Local time: 12:30

Section VI: Complementary information

- VI.1) **Information about recurrence**
This is a recurrent procurement: yes
Estimated timing for further notices to be published:
As per RFT
- VI.2) **Information about electronic workflows**
Electronic ordering will be used
Electronic invoicing will be accepted
Electronic payment will be used
- VI.3) **Additional information:**
- VI.4) **Procedures for review**
- VI.4.1) **Review body**
Official name: Irish Blood Transfusion Services
Postal address: National Blood Centre , James's Street
Town: Dublin
Postal code: D08 NH5R
Country: Ireland
E-mail:
- VI.5) **Date of dispatch of this notice:**
13/06/2023